Patent intelligence · US
US 11033623
Magnetic stem cell therapy for lesions
Magnetic stem cell therapy for lesions
Patent details — US 11033623
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jun 15, 2021
- Expiration
- Jun 10, 2041
- Applicant
- GREINER BIO-ONE NORTH AMERICA, INC.
- Claims
- 17
- CPC classes
- A61K, A61K2035/124, A61K35/28, A61K35/34
Quick answer
US 11033623 (Magnetic stem cell therapy for lesions) is held by GREINER BIO-ONE NORTH AMERICA, INC.. Status: granted. Granted Jun 15, 2021. Expires Jun 10, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- GREINER BIO-ONE NORTH AMERICA, INC.
- Grant date
- Expiration
- Claims
- 17
- CPC classes
- A61K, A61K2035/124, A61K35/28, A61K35/34, A61K35/35, A61K35/48
More from GREINER BIO-ONE NORTH AMERICA, INC.
Related pharmaceutical patents in our USPTO index.
-
US 12390512
Depolymerase capable of degrading extracellular polymeric substances of Klebsiella pneumoniae
granted -
US 10472381
Sialic acid derivatives
granted -
US 10265396
Magnetic extracellular matrix
granted -
US 9539228
Composition containing lysine as a nutritional supplement or treatment in the case of herpes
granted -
US 8309071
Foamy viral envelope genes
granted -
US 8293803
Retinoid compounds and their use
granted -
US 8268792
Use of an active ingredient combination that contains hydroxystilbene for preventing and/or treating diseases
granted
Frequently asked questions
What is US patent 11033623?
US 11033623 (Magnetic stem cell therapy for lesions) is held by GREINER BIO-ONE NORTH AMERICA, INC.. Status: granted. Granted Jun 15, 2021. Expires Jun 10, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11033623?
GREINER BIO-ONE NORTH AMERICA, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 11 pharmaceutical patents for this assignee.
When does US 11033623 expire?
Our index shows an expiration date of Jun 10, 2041 (15 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.